November Symposium: Duodopa® (2020)

In this webinar, Dr. Tara Rastin, a movement disorder specialist at the Pacific Parkinson Research Centre, delves into the complexities of Parkinson's disease, a neurodegenerative condition marked by dopamine-producing cell loss and specific brain protein buildup. Not all symptoms of Parkinson's respond to levodopa, the primary medication for managing its effects, prompting the exploration of alternatives like Levodopa Continuous Gel Infusion (LCIG) or Duodopa®. The webinar provides an overview of LCIG's function, highlighting the significance of patient preference, levodopa responsiveness, and meticulous symptom tracking.

Additionally, it underscores the crucial role of specialized evaluation and the involvement of a caregiver in the management of LCIG treatment for advanced Parkinson's. The process for administering LCIG includes referral to an educational program, involvement of a GI specialist for pump placement, gradual dosage adjustments, and continuous monitoring. While exercise doesn't replace medication, the webinar stresses the option of alternative treatments for symptoms unresponsive to levodopa.

View the video slides accompanying this presentation by clicking here.

**Disclaimer: These sessions are designed to provide general education and are not intended for individual advice and/or clinical care. The information conveyed in this recording was accurate at the time of presentation.**